Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme
Related Experiment Video
Updated: May 20, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Marko Spasic1, Frances Chow, Claire Tu
1UCLA Department of Neurosurgery, University of California, Los Angeles, Los Angeles, CA 90095-1761, USA.
Abstract:
This article provides historical background and current research involving the use of bevacizumab for the treatment of recurrent glioblastoma. Although bevacizumab, approved by the Food and Drug Administration, prolongs glioblastoma progression free survivial, decreases tumor vascularization, and reduces permeability of vessels, it does not seem to prolong overall survival. Despite slowed primary tumor progression, bevacizumab treatment may facilitate transformation to a more invasive phenotype. Adaptive responses, which make glioblastoma particularly resistant to various treatment modalities have been described. Conferred benefits, adverse effects, mechanisms of resistance, and potential areas for future research are discussed.
Insights
Bevacizumab (Avastin) helps recurrent glioblastoma patients live longer without progression but does not improve overall survival. This cancer drug may increase tumor invasiveness, highlighting adaptive resistance mechanisms.
Area of Science:
- Neuro-oncology
- Cancer biology
- Pharmacology
Background:
- Recurrent glioblastoma presents a significant therapeutic challenge.
- Bevacizumab is an anti-angiogenic drug targeting tumor vascularization.
Purpose of the Study:
- To review the historical background and current research on bevacizumab for recurrent glioblastoma.
- To discuss its benefits, adverse effects, and resistance mechanisms.
Main Methods:
- Literature review of bevacizumab in recurrent glioblastoma.
- Analysis of clinical trial data and preclinical studies.
Main Results:
- Bevacizumab prolongs progression-free survival and reduces tumor vascularization.
- Overall survival benefit remains unproven; potential for increased tumor invasiveness.
- Adaptive resistance mechanisms contribute to treatment limitations.
Conclusions:
- Bevacizumab offers palliative benefits in recurrent glioblastoma but does not overcome the disease's lethality.
- Further research is needed to understand and overcome resistance mechanisms for improved patient outcomes.
